Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.

MLA

Leccisotti, Lucia, et al. “Dapagliflozin Improves Myocardial Flow Reserve in Patients with Type 2 Diabetes: The DAPAHEART Trial: A Preliminary Report.” Cardiovascular Diabetology, vol. 21, no. 1, Sept. 2022, p. 173. EBSCOhost, https://doi.org/10.1186/s12933-022-01607-4.

APA

Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., Indovina, L., Ferraro, P. M., Iozzo, P., Crea, F., Giordano, A., & Giaccari, A. (2022). Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovascular Diabetology, 21(1), 173. https://doi.org/10.1186/s12933-022-01607-4

Chicago

Leccisotti, Lucia, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, et al. 2022. “Dapagliflozin Improves Myocardial Flow Reserve in Patients with Type 2 Diabetes: The DAPAHEART Trial: A Preliminary Report.” Cardiovascular Diabetology 21 (1): 173. doi:10.1186/s12933-022-01607-4.